C Mussini

L Bisi

L Manzini

R Esposito

V Borghi

Journal of the International AIDS Society

Crossref

Absence of liver steatosis in HIV-infected patients receiving tenofovir-containing regimen

Springer - Publisher Connector

BioMed Central
Page 1 of 1
(page number not for citation purposes)
Journal of the International AIDS 
Society
Open AccessPoster presentation
Absence of liver steatosis in HIV-infected patients receiving 
tenofovir-containing regimen
V Borghi*, C Mussini, L Manzini, L Bisi and R Esposito
Address: Clinic of Infectious Diseases, Modena, Italy
* Corresponding author    
Purpose of the study
Liver steatosis is a common and important histological
finding in hepatitis C, and is associated with an increased
progression of the disease. In HIV co-infected patients,
steatosis was independently associated with d-drugs, such
as stavudine, especially in non-3 HCV genotypes. We
investigate the safety of tenofovir disoproxil fumarate
(TDF) in determining hepatic steatosis in HIV/HCV co-
infected patients.
Methods
All consecutive HCV-infected patients who had under-
gone a liver biopsy have been included in this study. Pri-
mary outcomes were the presence or absence of steatosis,
or the presence of fibrosis.
Summary of results
370 HCV-infected patients underwent liver biopsy; 182
co-infected with HIV. Steatosis (>5% in liver biopsy) was
diagnosed in 33.0% of HCV mono-infected and in 47.3%
in HIV co-infected patients (OR 1.82; p = 0.005). Fifty HIV
patients (27.5%) were naïve to antiretroviral therapy.
Eighty-nine patients received stavudine for a median of 38
months (IQR 17.5–58), while 36 patients received tenofo-
vir for a median of 23 months (IQR 8.8–32). Factors asso-
ciated with steatosis were: genotype 3 (OR 3,14; p <
0.001), presence of fibrosis (OR 1.91; p = 0.039), dura-
tion of HCV infection (OR 1.10; p = 0.001) and use of d4T
in HIV patients (OR 3.00; p = 0.021). Considering only
patients with genotype 3, duration of HCV infection (OR
1.19; p = 0.001) and HCV RNA levels (OR. 1.04; p =
0.039) were the only determinants of steatosis. In HCV
genotype other than 3 the risk of steatosis was related to
fibrosis (OR 3.95; p = 0.002), use of d4T (OR 4.98; p =
0.014) and older age (OR 1.09; p = 0.014). In all cases use
of TDF was not associated with steatosis.
Conclusion
As previously described, the risk of steatosis is mainly
associated to HCV genotype 3 in patients infected by
HCV. HIV co-infected patients with genotype other than 3
are at risk of developing steatosis with stavudine but not
with tenofovir.
from Ninth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 9–13 November 2008
Published: 10 November 2008
Journal of the International AIDS Society 2008, 11(Suppl 1):P273 doi:10.1186/1758-2652-11-S1-P273
<supplement> <title> <p>Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection</p> </title> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1758-2652-11-S1-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1758-2652-11-S1-info.pdf</url> </supplement>
This abstract is available from: http://www.jiasociety.org/content/11/S1/P273
© 2008 Borghi et al; licensee BioMed Central Ltd. 


file:///data/core-remote/dit/data/Springer-OA/pdf/7a0/aHR0cDovL2xpbmsuc3ByaW5nZXIuY29tLzEwLjExODYvMTc1OC0yNjUyLTExLVMxLVAyNzMucGRm.pdf

Absence of liver steatosis in HIV-infected patients receiving tenofovir-containing regimen

Abstract

Similar works

Full text

Available Versions

Crossref

Springer - Publisher Connector

Springer - Publisher Connector